<table border="1"><tr><th>Trade names</th><td>Neurontin, others</td></tr><tr><th>Other names</th><td>CI-945; GOE-3450; DM-1796 (Gralise)</td></tr><tr><th>AHFS/Drugs.com</th><td>Monograph</td></tr><tr><th>MedlinePlus</th><td>a694007</td></tr><tr><th>License data</th><td>US |  DailyMed | Gabapentin | US | FDA: Gabapentin</td></tr><tr><th>Pregnancy | category</th><td>AU |  B1</td></tr><tr><th>Dependence | liability</th><td>Low</td></tr><tr><th>Addiction | liability</th><td>Low</td></tr><tr><th>Routes of | administration</th><td>By mouth</td></tr><tr><th>Drug class</th><td>Gabapentinoid</td></tr><tr><th>ATC code</th><td>N03AX12 ( | WHO | )</td></tr><tr><th>Legal status</th><td>AU |  S4 (Prescription only) | CA | : ℞-only | UK |  Class C | US |  ℞-only / Schedule V in some states</td></tr><tr><th>Bioavailability</th><td>27–60% (inversely proportional to dose; a high fat meal also increases bioavailability)</td></tr><tr><th>Protein binding</th><td>Less than 3%</td></tr><tr><th>Metabolism</th><td>Not significantly metabolized</td></tr><tr><th>Elimination | half-life</th><td>5 to 7 hours</td></tr><tr><th>Excretion</th><td>Renal</td></tr><tr><th>Identifiers</th><td>IUPAC name | 2-[1-(Aminomethyl)cyclohexyl]acetic acid</td></tr><tr><th>CAS Number</th><td>60142-96-3</td></tr><tr><th>PubChem | CID</th><td>3446</td></tr><tr><th>IUPHAR/BPS</th><td>5483</td></tr><tr><th>DrugBank</th><td>DB00996</td></tr><tr><th>ChemSpider</th><td>3328</td></tr><tr><th>UNII</th><td>6CW7F3G59X</td></tr><tr><th>KEGG</th><td>D00332</td></tr><tr><th>ChEBI</th><td>CHEBI:42797</td></tr><tr><th>ChEMBL</th><td>ChEMBL940</td></tr><tr><th>PDB ligand</th><td>GBN ( | PDBe | , | RCSB PDB | )</td></tr><tr><th>CompTox Dashboard | ( | EPA | )</th><td>DTXSID0020074</td></tr><tr><th>ECHA InfoCard</th><td>100.056.415</td></tr><tr><th>Formula</th><td>C | 9 | H | 17 | N | O | 2</td></tr><tr><th>Molar mass</th><td>171.240 |  g·mol | −1</td></tr><tr><th>3D model (JSmol)</th><td>Interactive image</td></tr></table>